Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 7, 2017

UK scientists assess ovarian cancer drug for brain tumours

A clinical trial (OPARATIC) funded by Cancer Research UK has evaluated the use of an ovarian cancer drug, olaparib, for the treatment of a type of brain tumour called glioblastoma.

A clinical trial (OPARATIC) funded by Cancer Research UK has evaluated the use of an ovarian cancer drug, olaparib, for the treatment of the glioblastoma type of brain tumour.

Olaparib is a PARP inhibitor designed to prevent damaged cancer cells from repairing themselves following chemotherapy or radiotherapy.

The trial investigated the ability of the drug to cross the blood-brain barrier to reach the tumour.

According to the results from 48 patients, olaparib combined with chemotherapy drug temozolomide successfully reached the tumours at the levels high enough for treatment of the disease.

The trial involved analysis of tumour samples that revealed penetration of the drug also to the surrounding areas having smaller amount of cancerous cells, which cannot be removed by surgery.

“While overall survival for cancer is improving, survival for brain tumours is still very low and the blood-brain barrier is a significant pharmacological obstacle.”

During the trial, researchers have further identified a method for safe combination of olaparib and temozolomide with intermittent administration of olaparib to reduce side-effects.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Cancer Research UK drug development director Dr Nigel Blackburn said: “While overall survival for cancer is improving, survival for brain tumours is still very low and the blood-brain barrier is a significant pharmacological obstacle.

“Experimental trials like this, which test new ways to reach these hard to treat tumours, are crucially important if we are to see more patients survive their cancer.”

Based on the results from the OPARATIC trial, two separate clinical trials PARADIGM and PARADIGM-2 are being conducted to evaluate the combination with radiotherapy in patients with newly diagnosed glioblastoma.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU